CNM-Au8

Other

Filedsubmitted

Evidence outlook · regulatory review

Amyotrophic Lateral Sclerosis: application submitted to FDA

Clene submits an NDA to the FDA seeking accelerated approval of CNM-Au8 for ALS (2026-10). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Latest reported trial: NCT04414345 · Phase 2/3 · missed primary endpoint · grade pending

Also in development:Multiple Sclerosis · Phase 2/3Parkinson's Disease · Phase 2

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 2/3 (2)
Amyotrophic Lateral Sclerosis
Multiple Sclerosis
Phase 2 (6)
Amyotrophic Lateral Sclerosis
NCT03843710 · Clene Nanomedicine
2020-03 – 2022-03 · Amyotrophic Lateral Sclerosis
What this study did
Multiple Sclerosis
NCT03993171 · Clene Nanomedicine
2019-12-19 – 2025-07-31 · Multiple Sclerosis
What this study did
NCT03536559 · Clene Nanomedicine
2018-11-23 – 2022-07-12 · Relapsing Remitting Multiple Sclerosis, Optic Neuropathy, Optic; Neuritis, With Demyelination
What this study did
Parkinson's Disease
Phase 1 (1)
Other / comorbidity
NCT02755870 · Clene Nanomedicine
2015-04 – 2016-10 · Healthy Volunteers - Male and Female
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2/3 (1)
Amyotrophic Lateral Sclerosis
NCT04297683 · Merit E. Cudkowicz, MD
2020-06-14 – 2028-08 · Amyotrophic Lateral Sclerosis
What this study did

Competitive landscape

This drug's own stage for Amyotrophic Lateral Sclerosis: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
CNM-Au8: this drugPhase 2/3Nanoparticlemitochondrial energy metabolismnot yet gradedNo reviewed efficacy summary in this indication
Edaravone (Radicava ORS)ApprovedSmall moleculeReactive oxygen species (ROS)Weak signalFeatured results are safety only in this race
Tofersen (Qalsody)ApprovedRNA / oligonucleotideSOD1Partial signalNo reviewed efficacy summary in this indication
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesnot yet gradedNo reviewed efficacy summary in this indication
UlefnersenPhase 3RNA / oligonucleotideFUSReliable signal
NCT04768972: FUSION (NCT04768972): ulefnersen met its primary endpoint, a joint rank (win-ratio style) analysis of time to death/permanent ventilation, time to rescue, and change in ALSFRS-R score to Day 505 vs placebo; p=0.0005.
CB03-154Phase 2/3Small moleculeKCNQ2/3 (Kv7.2/7.3) potassium channel (opener)not yet gradedNo reviewed efficacy summary in this indication
IbudilastPhase 2/3Small moleculePDE4 and PDE10; macrophage migration inhibitory factor (MIF)not yet gradedNo reviewed efficacy summary in this indication
Tazbentetol (SPG302)Phase 2/3Small moleculeDendritic spine densityWeak signalFeatured results are safety only in this race
DazucorilantPhase 2Small moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
ForalumabPhase 2Monoclonal antibodyCD3not yet gradedNo reviewed efficacy summary in this indication
ALN-SODPhase 1/2RNA / oligonucleotideSOD1not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

October 2026Filing submittedClene submits an NDA to the FDA seeking accelerated approval of CNM-Au8 for ALS
US, FDA · Clene Inc. · Source ↗